Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., July 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Leslie Norwalk, Esq., will join its Board of Directors. Ms. Norwalk provides strategic counsel to a number of biotechnology companies and served in the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). “Leslie’s impressive experience gives her an acute understanding of healthcare policy and the health insurance industry and will make her insight incredibly valuable as we prepare to navigate the regulatory and reimbursement landscapes,” said John Houston, Ph.D., President and CEO of Arvinas. “As our programs move through the clinic, her advice and counsel will be a great asset, and we’re excited to welcome her to the Board.” “As an advisor for companies developing new and cutting-edge therapies, it is my goal to ensure that as many pati
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) [Yahoo! Finance]Yahoo! Finance
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)GlobeNewswire
- Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress [Yahoo! Finance]Yahoo! Finance
ARVN
Earnings
- 5/7/24 - Beat
ARVN
Sec Filings
- 5/16/24 - Form 144
- 5/16/24 - Form 8-K
- 5/15/24 - Form 144
- ARVN's page on the SEC website